Macau, Hong Kong, and Singapore at a Glance
Macau: pragmatic and relatively flexible
Based on our local team’s experience, Macau is the most flexible of the three markets. In practice, foreign serious ICSRs are generally not handled as a rigid blanket expedited-reporting category unless they have a clear bearing on the local registration or local public health. Non-serious foreign cases are typically dealt with through periodic safety updates rather than one-by-one expedited submissions. Our team also views CIOMS as broadly acceptable in Macau, with no mandatory XML/E2B requirement identified in practice at this stage.
That practical read fits the tone of the public ISAF materials, which are broad and form-based rather than highly prescriptive. ISAF’s published ADR guidance says suspected ADRs are reportable whether serious or non-serious, and provides a local ADR form plus submission channels including email and the online reporting system, but it does not publicly spell out a detailed foreign-ICSR technical framework in the way some larger regulators do.
Singapore: structured and rules-driven
Based on our local team’s summary, Singapore is the clearest and most rules-based market operationally: serious foreign ICSRs are treated on an expedited 15-calendar-day timeline, while non-serious foreign cases are generally handled through periodic safety reporting rather than case-by-case expedited filing. Our team also notes that CIOMS I is standard and widely accepted, with electronic submission capability available.
Public HSA guidance strongly supports the broader picture that Singapore runs a highly structured post-marketing PV system with defined reporting timelines, CIOMS I for serious case submissions, and a formal PBRER framework where required. HSA’s published guidance is even narrower on foreign case reporting than the practical summary above: it states that overseas AEs occurring outside Singapore are not routinely reportable, while serious AEs that are reportable to HSA are due within 15 calendar days, and HSA may require PBRERs every 6 months for the first 2 years and annually for the next 3 years for specific products.
Hong Kong: focused less on blanket foreign case submission, more on local ADRs and material overseas actions
Based on our local team’s view, Hong Kong sits in the middle: it is less about automatic expedited reporting of every foreign serious ICSR, and more about whether an overseas safety issue is material to Hong Kong use. In practice, the market is viewed as more flexible than Singapore on routine foreign cases, but more attentive to important overseas regulatory or safety actions, which the team flags as a key operational point. CIOMS is commonly used, and non-serious foreign cases are generally handled through periodic or aggregate safety review rather than expedited case filing.
That is directionally consistent with the public Hong Kong framework. The Drug Office’s marketed-product ADR guidance is centered on ADRs occurring in Hong Kong, requires local serious ADRs to be reported within 15 calendar days, and allows use of either the DH ADR form or CIOMS form. Separately, for certain products such as new chemical or biological entities, Hong Kong’s registration guidance includes pharmacovigilance conditions around overseas regulatory actions, as well as PSURs every 6 months for the first 2 years and annually for the following 3 years, showing that Hong Kong’s system can combine local ADR reporting with product-specific overseas safety obligations.
Key PV Concepts: ADRs, ICSRs, Serious vs. Non-Serious Cases
Before getting into timelines and local filing mechanics, it helps to separate the core concepts that sit underneath every post-marketing pharmacovigilance system. In Hong Kong, an adverse drug reaction is defined as a response that is noxious and unintended to a pharmaceutical product. In Macau, ISAF’s ADR guidance uses very similar language and describes an ADR as an expected or unexpected noxious and undesirable patient response suspected to be associated with the use of a drug at normal doses. Singapore’s HSA guidance uses the term adverse event in place of adverse effect in its post-marketing guidance, and then applies its reporting rules through seriousness and causality criteria.
An ICSR, or Individual Case Safety Report, is the case report itself rather than the medical event. Put simply, it is the document used to capture one suspected side effect in one patient. Internationally, that case-reporting function is commonly handled through CIOMS I or, where electronic transmission is used, ICH E2B(R3). In this region, HSA instructs companies to complete the CIOMS I form for serious adverse event reports, while Hong Kong’s Drug Office accepts either its own ADR report form or the CIOMS form. Macau’s public materials are also built around a standard ADR report form and an online reporting route, and where local practice is more nuanced than the public documents, this guide follows our Macau team’s direct on-the-ground view.
The most important triage question is whether a case is serious. Hong Kong defines a serious ADR as one that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is a medically important event or reaction. Singapore uses essentially the same seriousness framework in its post-marketing guidance and adds two useful interpretive points: “life-threatening” means the patient was actually at risk of death at the time of the event, and medical judgment should still be used for important events that may jeopardize health even if they do not immediately result in death or hospitalization. Macau’s published ADR guidance is framed more practically, but it likewise points to worsening condition, hospitalization or prolonged hospitalization, significant disability or incapacity, life-threatening events, and death as seriousness markers.
Non-serious cases are, in practical terms, the cases that do not meet those seriousness criteria. That does not make them unimportant. Non-serious cases still matter for trend analysis, signal detection, and aggregate benefit-risk review over time. Macau’s public ADR guidance is notably broad on this point: it says suspected ADRs may be reported whether serious or non-serious, with or without confirmed causality, and even if all relevant information is not yet available. Singapore’s HSA guidance also makes clear that non-serious cases are not simply ignored: even where they are not routinely expedited-reportable, records still need to be maintained and made available on request.
This is also where the distinction between case-based reporting and periodic reporting becomes important. An individual serious case may trigger expedited local reporting, while non-serious or broader global safety information is often handled through periodic benefit-risk review. HSA states that a PBRER provides a comprehensive, concise, and critical analysis of new or emerging information on a product’s benefit-risk profile, and for selected products HSA may require submission every 6 months for the first 2 years and annually for the next 3 years. Hong Kong’s registration guidance for new chemical or biological entities similarly requires PSURs or equivalent reports every 6 months for the first 2 years and then annually for the following 3 years.
As a practical working rule, companies usually ask four questions in sequence. First, is this an ADR or adverse event potentially related to the product? Second, is there enough information to form a valid case report? Third, does the case meet seriousness criteria? Fourth, does it belong in an expedited local submission, or in aggregate periodic safety reporting? Those underlying concepts are broadly standard across Macau, Hong Kong, and Singapore, even though the local handling of foreign cases, local cases, and periodic submissions differs from market to market.
Market-by-Market Reporting Requirements
Singapore
Based on our local team’s operating view, serious foreign ICSRs should be exchanged and handled on a 15-calendar-day timeline, while non-serious foreign ICSRs are generally managed through periodic safety reporting rather than expedited case-by-case submission. CIOMS I is the standard format, and electronic submission is supported.
Public HSA guidance supports the broader structure on format, timelines, and periodic reporting. HSA states that serious adverse events reportable to HSA are due within 15 calendar days, that CIOMS I should be used for serious adverse event reporting, and that PBRERs may be required for certain products on a 6-monthly then annual cycle. HSA’s published guidance is narrower on foreign cases specifically, stating that overseas adverse events occurring outside Singapore are not routinely reportable.
Hong Kong
Based on our local team’s view, Hong Kong is less focused on blanket expedited filing of every foreign serious ICSR and more focused on whether the issue is material to local use. Serious foreign cases are not necessarily all subject to automatic expedited reporting, but important overseas safety issues and overseas regulatory actions affecting Hong Kong-registered products should be watched closely. Non-serious foreign ICSRs are generally handled through periodic or aggregate safety review rather than expedited submission. CIOMS is an accepted format.
The public Hong Kong framework is centered on local ADRs. The Drug Office guidance says serious ADRs occurring in Hong Kong should be reported as soon as possible and no later than 15 calendar days, and that either the DH ADR report form or the CIOMS form may be used. Separate Hong Kong pharmacovigilance conditions also require certain overseas regulatory actions to be notified and can require PSUR submission on a 6-monthly then annual basis for some products.
Macau
Based on our local team’s experience, Macau is the most flexible of the three markets. Serious foreign ICSRs are generally not treated as a rigid routine expedited-reporting category unless they are directly relevant to the local registration or local public health. Non-serious foreign ICSRs are generally handled through periodic updates or broader safety review. CIOMS is broadly accepted in practice, and no mandatory XML or E2B requirement has been identified by the local team.
The published ISAF materials are consistent with a broader, less prescriptive framework. They say suspected ADRs may be reported whether serious or non-serious, expected or unexpected, and whether or not all information is yet available. They also provide a local ADR reporting form, email/fax submission routes, and an online ADR reporting system, but do not publicly set out a detailed foreign-ICSR technical regime in the same way as larger regulators.
Formats, Timelines, and Periodic Safety Reporting
Singapore
For serious reportable cases, the standard format is CIOMS I, and HSA also supports electronic submission. HSA’s published guidance requires serious adverse events that are reportable to HSA to be submitted within 15 calendar days, with follow-up information also submitted within 15 calendar days. For periodic reporting, HSA may require PBRERs for selected products every 6 months for the first 2 years and annually for the following 3 years, with submission due within 70 days for reports covering up to 12 months and 90 days for reports covering more than 12 months. Our local team’s practical summary also notes that electronic E2B/XML submission is supported.
Hong Kong
The accepted case-reporting formats are the Hong Kong DH ADR report form or CIOMS form. For marketed products, the published Drug Office ADR guidance requires local serious ADRs to be reported as soon as possible and no later than 15 calendar days. For periodic reporting, Hong Kong can require PSURs or equivalent safety reports every 6 months for the first 2 years and annually for the following 3 years after approval for products subject to those pharmacovigilance conditions, including products registered under the new chemical or biological entity framework. Hong Kong also requires certain overseas regulatory actions tied to clinical study results to be notified as soon as possible and in any event no later than 72 hours for products under that framework.
Macau
Based on our local team’s operating experience, Macau is the least rigid on format and timing. CIOMS is broadly accepted in practice, there is no mandatory XML or E2B requirement identified by the local team, and foreign non-serious cases are generally handled through periodic safety updates rather than expedited one-by-one reporting. Public ISAF materials are consistent with a more flexible, form-based system: they provide a local ADR reporting form, allow submission by email, fax, mail, or the online reporting system, and do not publicly set out the same detailed foreign-ICSR technical rules seen in larger markets.
Practical SDEA Considerations
For ACA Pharma, the cleanest SDEA structure is to keep the manufacturer’s global pharmacovigilance function as the primary intake and database owner, and avoid putting ACA Pharma nor our local affiliates in the middle of routine global case handling. In practical terms, hospitals, treatment centers, physicians, and patients should be able to report directly to the manufacturer’s global PV team through its global safety email, telephone line, web intake channel, or database-linked mailbox. That reduces delay, avoids duplicate data entry, and keeps the case in the manufacturer’s validated global system from the start.
ACA Pharma maintains a named local PV contact in each market, including Macau, Hong Kong, and Singapore. Those local PV contacts should coordinate with local hospitals and treatment centers, support local follow-up where needed, and handle any required local authority submissions. In other words, the manufacturer should own global intake and global case processing, while ACA should own local execution and local regulatory interface.
A practical SDEA for these markets should usually reflect the following points:
- Direct reporting to the manufacturer’s global PV team should be the default for hospitals, treatment centers, and other reporters.
- ACA Pharma should forward any report it does receive to the manufacturer’s global PV contact within the agreed contractual timeline, but the process should be designed to minimize ACA Pharma acting as a relay point.
- ACA Pharma should not be required to recreate aggregate reporting or maintain a parallel global safety database.
- The manufacturer should remain responsible for global case entry, medical assessment, coding, signal review, and global aggregate reporting.
- ACA Pharma’s local PV contact in each market should remain responsible for local awareness, local follow-up, and any required local authority submission in that jurisdiction.
- Regular email, telephone, and a designated global safety mailbox should be acceptable reporting channels; the SDEA should avoid unnecessarily restrictive intake mechanics unless a specific authority requires them.
- CIOMS should be treated as an operationally acceptable case format, but the agreement should also allow initial intake through ordinary safety reporting channels so that valid cases are not delayed waiting for a formal template.
- Contractual exchange timelines should be realistic. ACA Pharma should not be given artificial obligations that are tighter than local law or operationally necessary, especially where the manufacturer already has a direct global intake channel.
- For Hong Kong in particular, the agreement should separately address prompt notification of material overseas regulatory or safety actions, rather than trying to force every foreign case into the same expedited bucket.
- For Singapore and Macau, non-serious foreign cases are better handled through periodic safety reporting and broader safety review than through unnecessary case-by-case escalation.
- The agreement should clearly name the responsible local PV contact for each ACA Pharma market entity and the responsible global PV contact on the manufacturer side.
- A periodic reconciliation process is still helpful, but it should be light-touch and aimed at confirming completeness rather than duplicating the manufacturer’s global system.
The main drafting objective is simple: keep the manufacturer’s global PV system as the primary safety repository, let local reporters reach that system directly, and use ACA Pharma’s local PV contacts for what they are actually needed for: local follow-up, local coordination, and local submissions. That structure is usually cleaner, faster, and less error-prone than forcing ACA Pharma to sit in the middle of every case.
